Role of Reverse Transcriptase Inhibitors in the Treatment of Psoriasis (PSORTI-BIO)

Centre Hospitalier Universitaire de Nīmes

Status

Completed

Conditions

Psoriasis

Treatments

Drug: Generic antiretroviral

Study type

Interventional

Funder types

Other

Identifiers

NCT04274595

AOIGCSMerri/2018/PS-01

2019-002236-91 (EudraCT Number)

Details and patient eligibility

About

The investigators hypothesize that the inhibition of endogenous reverse transcriptase would: (1) reduce excess cytosolic DNA, stress initiating the inflammatory loop at the origin of psoriatic lesions, and (2) interrupt the loop and lighten lesions

Enrollment

8 patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patient suffering from plaque psoriasis for more than a year with at least one active skin lesion> 4 cm2 in the photo-protected area.
Patient using effective contraception (IUD, adapted pill, condom, etc.)
The patient must have given their free and informed consent and signed the consent form
The patient must be a member or beneficiary of a health insurance plan

Exclusion criteria

Patient with another form or stage of psoriasis
Patient on anti-cytokine treatment during the 6 months (180 days) before inclusion
Patient under systemic treatment based on (1) corticosteroids, (2) antibiotics, (3) methotrexate, ciclosporin, soriatane, hydroxyurea, apremilast or (4) PUVA, (5) UVB, (6) vitamin D3 during the 4 weeks (28 days) before inclusion
Patient on topical corticosteroid or retinoid treatment during the 2 weeks (15 days) before inclusion
Patient with renal insufficiency; taking nephrotoxic agents (aminoglycosides, multiple or high doses of NSAIDs, etc.); creatinine clearance less than 50 ml / min; serum phosphorus below 1.0 mg / dl (0.32 mmol / l).
Patient with active viral infection (HBV, HCV and HIV), or uncontrolled acute infection.
Patient with hypersensitivity to one of the active substances or to any of the excipients (non-medicinal ingredients).
Patient with uncontrolled coagulation disorder, history of keloid scars
Patient with an allergy to local anesthetics; any condition likely to interfere at the time of the pre-inclusion visit, with the evaluation of the main objective such as eczema, psychiatric disorders
Patient with uncontrolled systemic parameters The subject is participating in an interventional study, or is in a period of exclusion determined by a previous study